Castle Biosciences Inc

Healthcare · Diagnostics & Research

33.70$ +2.2% vs. previous close Closing price · As of: Oct 8, 2026

Statements

Balance Sheet

Castle Biosciences Inc (CSTL) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 561 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet CSTL
Line item	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Total Assets	0.0	–	–	22	31	33	113	120	120	202	210	439	437	436	434	463	444	458	458	447	427	425	436	453	459	487	515	531	502	545	563	579	548	561
Current Assets	1.2	–	–	18	27	29	110	117	117	196	201	430	427	392	390	354	336	305	299	292	271	269	280	296	296	320	345	360	349	349	358	361	329	341
Cash	-1.2	–	–	4.5	16	17	94	99	99	180	183	410	407	368	363	330	309	273	134	123	115	96	91	99	83	86	95	120	90	82	86	117	64	62
Cash & Short-Term Investments	1.2	–	–	4.5	16	17	94	99	99	180	183	410	407	368	363	330	309	273	266	259	232	226	230	243	239	260	280	293	275	276	288	300	262	267
Receivables	0.0	–	–	12	9.2	9.7	12	15	15	13	13	13	14	18	19	17	20	23	23	23	28	31	37	38	43	46	50	51	56	52	49	43	42	48
Inventory	0.0	–	–	0.9	0.8	0.6	0.8	1.2	1.2	1.7	1.7	2.2	2.3	2.1	2.4	2.0	2.4	3.4	3.8	4.0	4.5	6.1	5.8	7.9	7.6	8.0	6.6	8.1	6.8	8.4	8.7	10	10	11
Property, Plant & Equipment	0.0	–	–	–	1.7	1.7	1.8	2.1	2.7	5.0	6.6	7.1	7.8	8.1	8.9	17	17	18	26	26	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Goodwill	0.0	–	–	–	0.0	–	–	–	–	–	–	–	–	–	–	–	–	10	10	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11
Intangible Assets	0.0	–	–	0.0	0.0	–	–	–	–	–	–	–	–	33	32	89	87	122	120	116	113	111	109	107	104	102	100	96	67	93	91	89	87	84
Total Liabilities	0.0	–	–	32	29	37	31	35	32	44	44	24	19	20	22	51	47	37	46	48	42	47	50	62	56	63	74	75	61	89	96	108	86	91
Current Liabilities	0.0	–	–	6.7	5.3	12	9.2	15	15	28	30	21	18	19	21	25	40	28	32	36	30	34	36	48	32	39	44	49	37	51	55	69	49	57
Short-Term Debt	0.0	–	–	–	3.6	5.3	3.3	5.8	8.3	10	10	0.1	0.1	0.0	0.0	1.2	1.2	1.2	1.5	1.8	1.8	2.0	1.1	1.1	1.2	1.2	1.7	1.9	2.5	3.5	1.4	1.7	2.9	4.3
Accounts Payable	0.0	–	–	1.5	1.6	2.1	1.3	1.9	1.9	2.5	2.1	2.1	2.2	1.4	2.8	2.5	3.3	3.3	5.8	4.7	10.0	7.1	6.9	10	9.3	9.5	6.8	6.9	8.5	13	12	19	15	9.7
Long-Term Debt	0.0	–	–	–	24	24	22	19	17	15	12	–	–	–	–	–	–	–	–	–	–	–	–	–	10	10	10	9.7	8.9	8.1	10	9.6	8.4	7.2
Shareholders' Equity	-14	–	–	-10	2.0	-3.6	82	85	88	158	167	416	419	416	412	412	397	422	411	399	385	379	386	391	402	424	441	456	440	455	467	471	461	470
Retained Earnings	0.0	–	–	-57	-59	-60	-54	-52	-52	-53	-58	-62	-67	-76	-87	-94	-118	-120	-140	-161	-190	-209	-216	-218	-221	-212	-210	-200	-226	-221	-222	-224	-239	-241
Shares Outstanding	11	11	11	11	11	15	14	19	19	18	20	21	25	25	25	25	25	26	26	26	27	27	27	27	27	29	29	30	29	30	29	29	30	30

Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings